Literature DB >> 20635136

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.

Sumito Sato1, Charlotte Kopitz, Bettina Grismayer, Nathalie Beaufort, Ute Reuning, Manfred Schmitt, Thomas Luther, Matthias Kotzsch, Achim Krüger, Viktor Magdolen.   

Abstract

uPAR, the three-domain membrane receptor of the serine protease urokinase, plays a crucial role in tumor growth and metastasis. Several mRNA splice variants of this receptor have been reported. One of these, uPAR-del4/5, lacking exons 4 and 5, and thus encoding a uPAR form lacking domain DII, is specifically overexpressed in breast cancer and represents a statistically independent prognostic factor for distant metastasis-free survival in breast cancer patients. The aim of the present study was to examine the molecular and cellular properties of the encoded uPAR-del4/5 protein. To investigate the impact of the uPAR-del4/5 overexpression on in vitro and in vivo aspects of tumor progression (e.g., proliferation, adhesion, invasion, metastatic seeding, and/or metastatic growth), we combined the analysis of transfected cancer cell lines with a murine xenograft tumor model. Increased expression of uPAR-del4/5 in human cancer cells led to reduced adhesion to several extracellular matrix proteins and decreased invasion through Matrigel, while cell proliferation was not affected in vitro. Moreover, invasion of uPAR-del4/5 overexpressing cells was not altered by addition of urokinase, while that of uPAR-wild-type overexpressing cells was drastically increased. Accordingly, we observed that, in contrast to uPAR-wild-type, uPAR-del4/5 does not interact with urokinase. On the other hand, when overexpressed in human breast cancer cells, uPAR-del4/5 distinctly impaired metastatic dissemination and growth in vivo. We demonstrate that the uPAR-del4/5 mRNA splice variant mediates tumor-relevant biological processes in vitro and in vivo. Our results thus illustrate how tumor-specific alternative splicing can distinctly impact the biology of the tumor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635136     DOI: 10.1007/s10549-010-1042-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  Lung       Date:  2013-02-14       Impact factor: 2.584

2.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

3.  Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells.

Authors:  Mariaevelina Alfieri; Anna Li Santi; Luigia Meo; Valentina Giudice; Carmine Selleri; Pia Ragno
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

4.  Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.

Authors:  Matthias Kotzsch; Viktor Magdolen; Thomas Greither; Matthias Kappler; Matthias Bache; Christine Lautenschläger; Susanne Füssel; Alexander W Eckert; Thomas Luther; Gustavo Baretton; Peter Würl; Helge Taubert
Journal:  BMC Cancer       Date:  2011-06-25       Impact factor: 4.430

Review 5.  The role of the small GTPase Rab31 in cancer.

Authors:  Christelle En Lin Chua; Bor Luen Tang
Journal:  J Cell Mol Med       Date:  2014-12-03       Impact factor: 5.310

6.  Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.

Authors:  Bettina Grismayer; Susanne Sölch; Bastian Seubert; Thomas Kirchner; Sonja Schäfer; Gustavo Baretton; Manfred Schmitt; Thomas Luther; Achim Krüger; Matthias Kotzsch; Viktor Magdolen
Journal:  Mol Cancer       Date:  2012-08-24       Impact factor: 27.401

7.  Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.

Authors:  Anna Lehner; Viktor Magdolen; Tibor Schuster; Matthias Kotzsch; Marion Kiechle; Alfons Meindl; Fred C G J Sweep; Paul N Span; Eva Gross
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 8.  Tissue Specific Promoters in Colorectal Cancer.

Authors:  A R Rama; A Aguilera; C Melguizo; O Caba; J Prados
Journal:  Dis Markers       Date:  2015-11-15       Impact factor: 3.434

9.  A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.

Authors:  Anna Li Santi; Anna Gorrasi; Mariaevelina Alfieri; Nunzia Montuori; Pia Ragno
Journal:  Oncotarget       Date:  2018-06-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.